The Nature of Addiction and Recovery

Basic Substance Abuse for District Court Judges

James Finch, MD

Director of Physician Education: NC Governor's Institute on Substance Abuse Addiction Medicine Practice: Changes By Choice, PLLC Durham, NC

The Nature of Addiction and Recovery

- Models for understanding substance abuse and addiction
- Progression from use to abuse to dependence
- Abuse and addiction applied to abuse of prescription medications
- Basic elements of evidence based SA treatment
- Role and limitations of medication assisted treatment
- Elements of SA assessment and treatment matching

Pivotal Developments in the Approach to Substance Abuse Assessment and Treatment

Potential for effective interventions improved by **three major developments** in the field:

- Public Health "Continuum" Model
- Evidence Based Behavioral Therapies
- Neurophysiologic Research and Pharmacologic Adjuncts: Medication Assisted Therapy (MAT)

| _ | | | | |
|---|--|--|--|--|
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| _ | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| _ | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |

We Are a Drug Using Culture

- Alcohol
- Tobacco
- Caffeine
- Stimulant medications
- Sleeping pills
- Tranquilizers ("nerve pills")
- Analgesics/pain pills
- Illicit drugs

Drugs of Abuse: Legal and Illegal

- Nicotine
- Alcohol
- Marijuana and hashish
- Cocaine, amphetamines, MDMA ("ecstasy")
- Heroin, opioid analgesics (pain pills)
- Benzodiazepines, barbituarates
- Inhalants (solvents, gases, nitrous)
 Hallucinogens (LSD, mescaline, psilocybin)
 Other: Ketamine/PCP/DXM/Steroids
- NEXT?

Deaths Related to Drug Use (US Centers for Disease Control and Prevention)

■ tobacco

>430,000/year

■ alcohol

100,000/year

Overdose deaths:

■ abuse of Rx meds

>20,000/year

■ cocaine and heroin

15,000/year

Commonly Abused Prescription Medications

- Ranking of common classes of abused prescription medications in terms of frequency and public health impact:
- Opioid analgesics

 Hydrocodone (Vicodin)

 Oxycodone (Percocet, Oxycontin)


 Methadone (Dolophin)
- Benzodiazepines


 Alprazolam (Xanax)


 Clonazepam (Klonopin)


 Stimulants


- Amphetamine (Adderal)
 Methylphenidate (Ritalin)











The Next Generation

Increase in recreational use of opioid analgesics between 1992 and 2002:

Age 12 to 17: **542** % Age over 18: **124**%

Prevalent nationwide but higher in rural, suburban and small urban areas.

National Center on Addiction and Sub Abuse: Columbia U., 2005. Cicero TJ, et al. Pain Medicine, 2007.

Adolescent Prescription Medication Abuse:

Sources: 60%: Friend or relative

17%: Single physician


5%: Drug dealer 1%: Internet

SAMHSA: National Survey on Drug Use and Health, 2005

Reasons for using: Easy to get from medicine cabinet: 62%

Available everywhere: 52% They are not illegal drugs: 51% Safer to use than illegal drugs: 35% Easy to get over the internet: 32% Parents don't care as much if caught: 21%

NIDA: PATS Survey: Grades 7 through 12, 2005.



Public Health Paradigm of Prevention and Intervention for Alcohol and Other Drug Related Problems

The primary goals are to:

- 1. Prevent or delay the onset of use and/or prevent the progression of high-risk or problematic use.
- 2. Reduce high-risk or problematic use to lower-risk levels.
- $3. \ Promote \ abstinence \ in persons \ who \ are \ alcohol \ or \ other \ drug \ dependent.$

This presentation will focus on the last of these 3 goals although aspects will be applicable to the other two.

Progression Along the Continuum

- Continuum: Use-Misuse-Abuse-Dependence
- How does someone get from use to abuse?Why some and not others?Why them and not me?

- How do you go back?
 How do you prevent or intervene with the progression?
 How do you treat addiction?

Models for Addiction: Past and Present

■ Moral:

The addict is weak or bad. The drug itself is evil.

Psychological/Sociological:

"Addictive personality" Learned behavior: Reward theory Family and cultural norms

■ Medical "disease":

Genetic predisposition Neuro-chemical "imbalance" or adaptation

| Public Health Model of Disease Applied to Addiction | |
|---|----------|
| | _ |
| HOST ENVIRONMENT Genetic predisposition Availability/ease of access to drug | |
| Impulsivity/Self-colorol Social Skills/Relationships Age of first use Mental disorders Poverty/Opportunity Family cohesion/monitoring Peer attitudes/use Response to problem behaviors | |
| AGENT | |
| Positive Effect: psychotropic/physical Speed of onset/Duration of action Perceived safety or risk Side effects/Cost | |
| Side effects/Cost | <u> </u> |
| | |
| | |
| | |
| | <u> </u> |
| Host: Predisposing Factors | |
| ■ Predisposition based on: -genetics | |
| -impulsivity/risk taking -pronounced response to drug | |
| -early age of first use | |
| | II I |
| Increased risk from co-existing conditions: -mood disorders | |
| | |
| -mood disorders -trauma/PTSD | |

Environment: Cultural and Economic Factors

- Availability of drugs
 Poverty/opportunity
 Family cohesion/monitoring
 Response to problem behaviors
 Availability of treatment

- Peer and family attitudes
 Cultural norms about drug use

Cultural Ambivalence About Alcohol and Other Drugs

■ Source of serious morbidity and mortality

BUT

- Often socially acceptable
- Readily availableMany heavily promoted and advertised
- Consequences tolerated by society

US society and opioid analgesics

Percentages of world-wide production of opioid analgesics that are consumed in the US:


99% 83% Hydrocodone Oxycodone HydromorphoneMethadone 57% 60% Morphine 51%

International Narcotics Control Board: UN Pub. 2006

Agents: Characteristics of Drugs and Medications

- How do characteristics of certain drugs enhance or disguise their abuse potential?
- How do these characteristics interact with host and environment?
- How can characteristics of certain opioids even make them useful as treatments?

| - | |
|---|--|
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |



| 1 | Cocaine: 1 | Forms | and H | low I | Ised |
|---|------------|-------|-------|-------|------|
| | | | | | |

Coca leaves (chewed or as tea)
2% cocaine
Coca Paste (occasionally smoked)
20% cocaine
typically not exported
Cocaine Hydrochloride (snorted or injected)
90% cocaine
traditional powder form

Cocaine Base ("crack": smoked)
95% cocaine
small pebble sized/easily marketable

Onset and Peak Effects of Stimulants Related to Route of Administration

| Route | Onset of Action | Peak Effect |
|---------------------------|----------------------------|------------------------------|
| Inhalation | 7-8 seconds | 1-5 minutes |
| Intravenous Intranasal | 15-16 seconds 3 minutes | 3-5 minutes 15-20 minutes |
| Oral | 10 minutes | 45-60 minutes |

9

Opioid Characteristics: Abuse and Addiction or Treatment

| | Methadone Buprenorphine | Short acting opioid |
|----------|----------------------------|---|
| Route | Oral Sublingual | Oral, injected (IV), Intranasal (IN) |
| Onset | 60 min. or more | IV, IN: seconds Oral: 15-20 min. |
| Duration | 8 to 24 hrs. | 2 to 4 hours |
| Euphoria | Absent | Present: moderate to pronounced |

Review the progression from non-problematic use to abuse and dependence:

To provide a background for understanding the necessary core elements of treatment.

Why do people start using drugs?

- To feel good: get "high" or "buzzed" or "altered"
- To avoid emotional pain, relax or deal with stress: "chill" or "mellow out"
- To perform better, activate, energize or enhance: "rev" or "amp up"
- To be part of a group, socialize, conform: "fit in"
- Medical treatment of physical pain or psychiatric illness: "get relief"

| 1 | ſ |
|---|---|

Why do people keep using or escalate their use of drugs?

- Previous reasons with **expansion** into other domains
- Narrowing of behavioral alternatives/increased reliance on
- What's "good" about using **seems** to outweigh what's "not so good"
- Denying or **ignoring risk or problems** as they develop

Escalating Risks of Drug Use and Abuse

Risks associated with quantity/frequency/chronicity:

The more and the longer you use, the more likely you are to have problems.

Ex: Alcohol and liver disease Marijuana and lung disease

Risks associated with acute toxicity:

The characteristics of the drug or how it is used mandate risk at *any level* of use.

Ex: Cocaine and cardiac risk
Injecting behaviors and infectious disease risk
Drinking/drug use and trauma risk

■ Escalation of medical and psychiatric co-morbidities

Particular Risks Associated with Prescription Medication Use and Abuse: Subtle

- Escalating use in attempt to get relief from untreated pain or mood
- Over-reliance on meds for "chemical coping"
- Rationalizing problematic or high risk use because "it's prescribed
- Even if recognize problems, may see as "only way to deal with pain
- If try to wean or stop: withdrawal, untreated pain or mood disorders are strong triggers for relapse

| <u> </u> |
|--------------|
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |

Progression to Abuse and Dependence: Problems

- Increased use of the drug and time involved with the drug
- Development of recurrent pattern of problems related to use:
 Emotional/Interpersonal/Social
 Physical/Occupational/Legal
- Continued use of the drug in spite of these problems
- Increasing guilt/shame/denial

Progression to Abuse and Dependence: Neuro-adaptation

- Neuro-adaptation in reward (survival) system with increasing reliance on the drug to maintain hedonic tone.
- Deterioration in pre-frontal cortical control system and transition from volitional control to compulsive, out of control use.
- Transition from pleasurable use to maintenance use and need to avoid physical withdrawal.

Host: Altered Brain Physiology

Progression toward addiction is facilitated by:

- Neuro-plasticity in host in response to repeated drug exposure:
- Alterations in neuronal structure and neurotransmitters in three critical
 - areas of the brain:
 - -limbic system
 - -hippocampus
 - -prefrontal cortex

| - | | | |
|---|------|--|------|
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |

Neurotransmitters and Drugs of Abuse

- Dopamine
 -mediates motivation and reinforcement
 -increased release with drug use

- -increased release with drug use

 Serotonin
 -modulates mood, motivation, appetite
 -influences rewarding effects of drugs

 Endorphins
 -mediates rewarding effects, relief
- -mediates rewarding effects, refler
 -activates dopamine release
 GABA (gamma-amino butyric acid)
 -major inhibitory transmitter
 -enhanced by alcohol and other sedating drugs
- Glutamate
 -major excitatory transmitter
 -suppressed by alcohol or other sedating drugs

Dependence on Alcohol or Other Drugs

Maladaptive pattern of use leading to clinically significant impairment or distress, manifested within a 12-month period by at least 3 of the following:

- 1. Tolerance
- 2. Withdrawal
- Loss of control over amount consumed
- Preoccupation with controlling use
- 5. Preoccupation with related activities
- Impairment of social, occupational, or recreational activities
- Use is continued despite persistent problems related to use

DSM-IV-TR. American Psychiatric Association: Washington, DC; 2000.

"Bio-psycho-social-spiritual" **Treatment Elements**

- Time abstinent: re-set neuro-adaptation/restore cortical function
- Mitigate craving: MAT and behavioral interventions
- Address reasons for use and how to respond to and avoid triggers and cues
- Alternate means of coping with craving and dysphoria
- Decrease social risks: situations/settings/associates

Treatment Elements: continued

- Increase access and use of non-using behavioral alternatives
- Increase social support for sobriety/connect or reconnect
- Reinforce other sources of reward/pleasure
- Re-establish connection with spiritual or other source of meaning (god/family/community/meaningful work)

Treatment Alternatives to Facilitate Recovery

Mutual support/self-help groups
AA, NA, Al-Anon,Smart Recovery, Women for Sobriety

Psychosocial and non-pharmacologic treatments Cognitive Behavioral Therapy Motivational Enhancement Therapy Contingency or Incentive Based Therapy Family and Couples Based Therapies

Applied in individual and/or group therapy settings

Medication assisted treatments (MAT)

Dimensions of Substance Use Treatment

- · Levels of care
- Setting
- Duration
- Approach

| 1 | Δ |
|---|---|

Levels of Care: ASAM Placement Criteria

■ Based on 5 dimensions

Biomedical conditions

Emotional or cognitive condition Readiness to change Relapse, continued problems

Recovery environment

- Levels of Care: 0.5-4.0
 - 0.5 Early intervention
 - Outpatient Services
 - Intensive Outpatient

 - Residential/Inpatient Med Managed Inpatient

Settings for Treatment Within Each Level of Care

| LOC | Examples of Setting |
|-------|---|
| .5 | DUI programs, EAP services, eval only, mobile |
| ı | office practice, primary care, 2X weekly group |
| II.1 | intensive evening program (e.g. 5X/week, 5-8 hrs/day) |
| II.5 | day program (e.g. 5-7 X/week, 5-8 hrs/day) |
| III.1 | halfway house |
| III.3 | extended care facility |
| III.5 | therapeutic community |
| III.7 | inpatient rehabilitation center |
| IV | inpatient hospital detox or psych unit |

Approaches to the Treatment of Substance Use

- · Distinction between setting and approach
- Large number of approaches, differing in: conceptual understanding of addiction techniques employed
- Approaches can be practiced across a variety of treatment settings for variable duration

Treatment of Substance Abuse: Role of MD

Addiction Medicine physicians may have various roles in different settings and levels of care:

- Treatment of medical and/or psychiatric co-morbidities, including withdrawal management
- Providing medication assisted treatment (MAT) with or without involvement in non-pharmacologic treatment.
- Care related to Non-pharmacologic treatment: Provided directly by the MD Managed or supervised by the MD Supported and reinforced by MD

Review of Treatment Effectiveness Miller et al (1995)

- Meta-analytic review of 219 studies
- Ultimately able to rank 30 treatment approaches

Best Performing Approaches (not rank ordered)

- Motivational Interviewing
- Brief Interventions (usually motivational approach)
- Cognitive-Behavioral Treatment
- Community Reinforcement Approach (CRA)
- Contingency Management (CM)
- Behavioral Marital Therapy (BMT)
- Medication Assisted Treatments

| _ | | |
|---|--|--|
| _ | | |
| - | | |
| - | | |
| | | |
| | | |
| | | |
| _ | | |
| | | |
| | | |
| | | |
| _ | | |
| | | |
| | | |
| | | |
| _ | | |
| | | |
| | | |
| | | |
| - | | |
| | | |
| | | |
| | | |
| _ | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| - | | |
| | | |
| | | |
| | | |
| _ | | |
| | | |
| | | |
| _ | | |
| | | |
| | | |
| | | |
| _ | | |
| | | |
| | | |
| | | |
| - | | |
| | | |
| | | |
| | | |
| _ | | |
| | | |
| | | |
| | | |
| _ | | |
| _ | | |
| - | | |
| _ | | |
| _ | | |
| _ | | |
| _ | | |
| _ | | |
| _ | | |
| _ | | |
| _ | | |
| _ | | |
| _ | | |
| _ | | |
| _ | | |
| _ | | |
| - | | |
| - | | |
| - | | |
| - | | |
| - | | |
| - | | |
| | | |
| | | |
| | | |
| - | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |

Worst Performing Approaches (not rank ordered)

- · Educational approaches alone
- General counseling (usually disease model training)
- Psychotherapy (supportive, insight-oriented)
- · Confrontational counseling
- Relaxation training alone

Selected Psychosocial Treatments

- Motivational Interviewing (MI)
- Cognitive-Behavioral Treatment (CBT)
- · Community Reinforcement Approach (CRA)
- Contingency Management (CM)
- Family and Marital Therapy (BMT)
- Dialectical Behavioral Therapy (DBT)

Approaches in Addiction Treatment: Motivational Interviewing


- A directive, client-centered counseling style for eliciting behavior change by helping clients to explore and resolve ambivalence.
- · Recognizes that people make changes when:

They see themselves vulnerable to negative consequences and regard them as serious

They see the benefits of change outweighing the costs of change

Builds upon/distinct from Trans-theoretical Stages of Change Model

| |
|------|
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |



Stages of Change (1)

(Prochaska & DiClemente's Transtheoretical Model)

• Pre-contemplation

Awareness of association between risk or problems related to drug use move people out of this stage

• Contemplation

Perceived rewards of *changing* must increase and costs of changing must decrease: *resolve ambivalence*

• Preparation

Acceptance of need for change/plan implementation

Stages of Change (2)

Action

Most treatment is aimed at patients in this stage only:often a mismatch between readiness and plan

• Maintenance

Requires ongoing work to sustain changes

• Termination

Less than 30% make this stage

• (Relapse)

Ongoing risk but doesn't mean "going back to square one"

| Two Stages of Motivational Interviewing | |
|--|----------|
| ■ Phase 1: Building Motivation for Change | <u> </u> |
| | |
| ■ Phase 2: Strengthening Commitment to Change | <u> </u> |
| | |
| | |
| | |
| | |
| | |
| | |
| | ā |
| Change Talk | |
| Change Talk | |
| Change talk is any client speech that favors movement in the direction of change | |
| ■ Previously called "self-motivational statements" | <u> </u> |
| Change talk is by definition linked to a particular behavior | <u> </u> |
| change target | |
| | |
| | |
| | |
| | |
| | |
| | ī |
| Preparatory Change Talk (Building Motivation) | |
| | |
| ■ DESIRE to change (I want towould like towish I could) | |
| ■ ABILITY to change(I could) | |
| ■ REASONS to change (If I couldthen) | |
| ■ NEED to change (I need to have to) | |
| | |
| | · |

Implementing Change Talk

Reflects resolution of ambivalence:

- COMMITMENT (intention, decision, readiness)
- ACTIVATION (willing, trying, preparing)
- TAKING SPECIFIC STEPS
 - "I have decided to..."
 - "I am willing to..."
 - "I am doing this...and this..."

Motivational Interviewing (MI) helps to:

- Enhance intrinsic motivation for change (mobilize client's own change resources)
- Recognize the need to do something about the current or potential problem
- Resolve ambivalence and reach a decision for change
- Build commitment to change

Cognitive-Behavioral Therapy (CBT): Rationale

- Substance use can be seen as learned behavior
- Over time, substance use affects how people think and feel, and what they do
- By understanding this process, one can learn how to stop or change use
- New, more effective skills can replace old habits that lead to use
- Practice is essential

| | _ |
|--|---|
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |

Cognitive Behavior Therapy: Basic Treatment Components

- Identification of high risk situations "people, places, and things"
- Development of coping skills
 To manage risk/triggers as well as negative emotional states
- Development of new lifestyle behaviors

 To decrease need for/role of substance use
- Development of sense of self-efficacy
 Build on small successes in coping

Core Elements of CBT: Recognize/Avoid/Cope

- Recognize: triggers/cues (external/internal)
- Anticipate/Avoid: (situations/people/places)

"People/Places/Things"
"Playmates/Playgrounds/Playthings"
"Play the tape to the end."

"It is easier to avoid temptation, than to resist temptation".

Cognitive Behavior Therapy: Basic Treatment Components (2)

- Communication skills
 Drink refusal skills
 Asking for help
- Preparation for lapses
 Process to be learned from "lapses"
 Prevent lapse from becoming relapse
 Identify and manage patterns of thinking that increase risk
- Dealing with relapse
 Relapse is not a catastrophe
 Minimize consequences

Core Elements of CBT Applied to Substance Abuse Treatment

■ Cope: develop or reinforce skills:

Deal with cravings/urges to use/situations Explore other ways to relax/deal with stress/problem solve Re-expand dormant behavioral options to socialize/have fun Connect/re-connect with sources of reward and "hedonic tone"

"Who needs life when you've got heroin." (Trainspotting)

CBT: Editing the Patient's "Story"

The language of the story: Generalizations Distortions/delitions

Therapeutic interventions:
Challenging "learned helplessness"
Reinforcing the power of "yet"
Supporting "self-efficacy"

Support Self-Efficacy: Editing the Patient's "Story"

Listen to the *language* of the patient's story: generalizations/deletions/distortions

"I always screw up" "I can't stop using" "My life is still crap" Therapeutic interventions:

Challenging "learned helplessness"

"Really, you always screw up?"

Reinforcing the power of "yet"

"Well, yes...you haven't stopped... yet"

Supporting "self-efficacy"

"Look what you have accomplished...you can do this"

Contingency Management (CM)

- Based on operant conditioning: substance use as learned behavior
- Contrived rather than naturally occuring: uses contingencies set in place explicitly and exclusively for therapeutic purposes
- Example: Earning vouchers exchangeable for retail products contingent on negative urine toxicology results
- Example: Earning methadone take-home privileges for negative urine drug screens

Community Reinforcement Approach (CRA) Basic Treatment Components

- Based on operant conditioning: substance use as learned behavior
- Naturalistic: uses contingencies already operating in the individual's natural environment to support change and abstinence (eg: giving or withholding praise for behaviors)
- Functional analysis of both healthy and substance use behaviors in terms of ability to reward/be aversive
- Refining problem-solving and goal-setting efforts for individual and/or family (teaching positive communication, contracting skills)

Approaches in Addiction Treatment: Treatment for Significant Others

 Types of Family/Marital Treatment (alone or together with identified patient)

CRAFT: Community Reinforcement and Family Training

Behavioral Marital Therapy (BMT)

| - 4 |
|-------|
| - |

| Community | Reinforcement | and | Family | Training | 2 |
|-----------|---------------|-----|--------|----------|---|
| • | (CRAF) | | • | · | _ |

- Only Concerned Significant Other (CSO) present for sessions (identified substance user not present)
- · Usually individual sessions
- Behavioral focus on reinforcing/rewarding abstinent behaviors and removing inadvertent reinforcers of substance use
- Behavioral clinical tools employed, e.g. role plays, problem-solving, self-reports (Happiness Scale) to focus self-care efforts and improve communication skills

Behavioral Marital Therapy (1)

Treatment based on group couples therapy
 Initial 6-8 session conjoint meetings (including Antabuse contracting)

Couples weekly group lasting 10 sessions

Must accept sobriety as a goal

Must be lack of significant threat of violence

Behavioral Marital Therapy (2)

- Alcohol and alcohol-related interactions
 Review Antabuse contract
 Review cravings/urges
 Relapse prevention
- Increase positive activities/interactions
 Notice, acknowledge, & initiate caring behavior
 Increase shared pleasant activities

| |
|------|
| |
| |
| |
| |
| |
| |
| |
| |
| |

Behavioral Marital Therapy (3)

- Communication skills training
 Listening and speaking skills
 Direct expression of feeling
- Negotiation of behavior change
 Learning positive specific requests
 Negotiation and compromise skills

Treatment of Co-morbid Emotional Issues

- Characterologic/Coping Skills Deficiencies:
 Dialectical Behavioral Therapy (DBT)
 Anger management skill building
- Trauma history (after stable recovery):
 DBT
 EMDR
- Psychiatric Axis I Co-Morbidity:
 Medication and behavioral therapies

Dialectical Behavior Therapy (DBT): Basic Treatment Components

- Manualized behavioral treatment utilizing validation and motivational enhancement techniques
- Often combination of group and individual elements
- Addresses enhancement of 4 basic capabilities:

Interpersonal effectiveness Emotional and self regulation capacities Ability to tolerate distress Mindfulness

| - | |
|---|--|
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |

Developing Coping Strategies:

- Coping with craving
- Coping with:

Emotional triggers/dyphoria

Anger

Anxiety

- Role of mindfulness
- Role of non-using fun

Emotion Regulation

Most people think the sequence goes:

Event → Emotion → Action

Instead, we teach:

Event → Self-Talk → Body Response → Emotion → Action

And encourage patients to have sober FUN regularly to offset events they can't control.

Distress Tolerance

- ...how to get through difficult situations when you can't solve the problem (right away, or at all) without making things worse (using).
- Distractions
- Prayer, meaning
- Self-soothing
- (Radical) Acceptance

| - | | |
|---|--|--|
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| - | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| - | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |

Behavioral Therapies: Groups

- Modal format for substance abuse psychotherapy:
 More economical than individual therapy
 All major schools of individual therapy have been adapted to group
- Advantages:

Modeling, varied coping skills Public affirmations, confession, support Networks of support

| D 1 ' 1 | TD1 . | T 1' ' 1 1 |
|------------|------------|------------|
| Behavioral | Therapies: | Individual |
| | | |

- Privacy
- Flexibility to address issues as they arise
- Focus on unique individual relevant issues
- More practical size for some providers
- Avoidant patients may do better (e.g. schizophrenics, traumatized)

Role of Medication in in Substance Abuse Treatment

- Withdrawal management
- Psychiatric co-morbidity
- To support primary addiction treatment: "Relapse Prevention" "Anti-Craving"

Medication Assisted Treatment for Primary Addiction Treatment

Demonstrated efficacy and FDA approval:

- Alcohol:
 - disulfiram, naltrexone, acamprosate
- Nicotine:
 - nicotine replacement, buproprion, varenicline
- Opioids:
 - agonist: methadone, buprenorphine/naloxone
 antagonist: naltrexone

Preliminary findings of efficacy for Cannabinoids/Cocaine

All efficacy demonstrated in combination with participation in non-pharmacologic treatment.

MAT for Opioid Abuse: Agonist/Substitution Therapy

- · Rationale for Substitution Therapy:
 - Cross-tolerance
 - Prevents withdrawal
 - Relieves craving
 - Blocks euphoric effects of other opioids
 - Appropriate for illicit or prescription opioid abuse
- Available alternatives:
 - Methadone: dispensed through licensed opioid treatment program (OTP)
 - Buprenorphine (Subutex/Suboxone): prescribed through office based opioid treatment (OBOT)

Buprenorphine: Benefits of Pharmacology

- 1. Partial agonist
 - -results in a 'ceiling effect' on respiratory depression -has a lower reinforcing effect than full agonist
- 2. Slow onto the receptor minimizing euphoria
- 3. Very high affinity for the mu receptor
 - -results in the ability to displace other opioids
 - -makes it difficult for other opioids to displace it
 - -results in easier taper and withdrawal

Antagonist Tx. for Opioid Dependence: Naltrexone

- Antagonist: naltrexone binds with and blocks opioid receptors
- Available as an FDA approved oral preparation (ReVia)
- Compliance improved by monitored dosing
- IM sustained release (monthly) preparation available (Vivitrol)
- Recently FDA approved for alcohol dependence as well as opioid dependence

Adjunctive Medications for Cocaine and Other Stimulants

■ Disulfiram (Antabuse)

Clearest efficacy in co-morbid alcohol/cocaine abuse by elimating use of alcohol

■ Stimulant agonist medications:

Modafinil (Provigil)
Methylphenidate (Ritalin)

GABA active agents:

Baclofen Topiramate (Topamax) Tiagabine (Gabitril)

Vocci FJ et al. American J of Psych Kenna GA et al. CNS Drugs. 2007


Medication Assisted Treatment: Is It Effective?

- Literature review and meta-analysis: 2003:
- More effective than non-pharmacologic approaches in terms of retention in treatment and decreased opiate use.
- In clinical trials shown to reduce opiate use greater than drug-free treatment or detoxification.
- No difference in outcome between buprenorphine and methadone.
- Mattick, RP, et al: MMT Versus No Opioid Replacement Therapy for Opioid Dependence. Mattick, RP, et al: Buprencrphine versus Placebo or Methadone. The Cochrane Library, 2003

| | _ | | |
|--|---|--|--|
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |

Assess/Treat/Monitor/Adjust

- Adequate assessment for:
 Diagnosis of abuse or dependence
 Withdrawal risk
 Medical and psychiatric co-morbidities
- Assess readiness to change
- Develop treatment plan/treatment matching
- Monitor and adjust treatment plan as ongoing process



Assessment: Comprehensive

- Quantify/frequency/duration
- Impact on life/relations/performance/legal:
 - Physical -Psychological -Family
 - Job -Legal
- Evaluate for psychiatric co-morbidity
- Evaluate for medical consequences
 - Trauma -Depression -Insomnia
 - Hypertension -GI Symptoms
- Evaluate lab data/Drug Screens
- Assess recovery environment
- Assess Readiness to Change

Assess Pattern/Consequence Systematically

- AUDIT Alcohol Use Disorders Identification Test
 - WHO 1989, 10 Questions, 5 minutes
 - Hazardous Use or Harm to Health
 - #1-3: Quantity/frequency
 - #4-10: dependence + consequences
 - Validated performance across wide variety of settings, gender, nationalities

Assess Consequences Systematically

- Addiction Severity Index (ASI) (1980, 1985, 1992)
 - Semi-structured interview
 - Validated in wide range of settings
 - Useful for treatment planning and outcome evaluation
 - 1 hour administration by interviewer
 - Computerized scoring available

ASI Composite Scores

- Past 30-day Severity of Problems (scores 0.0-1.0)

 - Medical
 Employment
 Alcohol Use

 - 4. Drug Use

 - 5. Legal6. Family/Social7. Psychological

Assess Consequences Systematically

■ MAST & SMAST & BMST

(Michigan Alcoholism Screening Tests: Original, Short, Brief)

- 25-, 13-, or 10-Item Questionnaires
- Self-administered, rapid, effective
- Lifetime Alcohol-related Problems/Alcoholism

Assess Consequences Systematically

- SAAST (Self-Administered Alcoholism Screening Test)
 - 37-items, MAST-like,
 - Copyrighted Mayo Clinic
 - Questions include: loss of control, occupational & social disruption, emotional consequences, concerns of family & friends
 - Administered by patient, family, or friend

Assess Withdrawal Systematically

CIWA-Ar: Clinical Institute Withdrawal Assessment for Alcohol–Revised)

- Addiction Research Foundation, Toronto
- Initial assessment/ongoing monitoring of withdrawal
- Evaluated only for treatment settings
- 10 Parameters, scored on scales of 1-7
- Objective and subjective types measures
- High inter-rater reliability

| • | |
|---|--|
| | |
| | |
| | |
| | |
| • | |
| | |
| | |
| | |
| | |
| • | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |

Diagnose by DSM IV Criteria: Dependence

Maladaptive pattern of use leading to clinically significant impairment or distress, manifested within a 12-month period by at least 3 of the following:

- 2. Withdrawal
- Loss of control over amount consumed
- 4. Preoccupation with controlling use
- 5. Preoccupation with related activities
- Impairment of social, occupational, or recreational activities
- 7. Use is continued despite persistent problems related to use


DSM-IV-TR. American Psychiatric Association: Washington, DC; 2000.

Bottom Lines Regarding Evaluation for Rx Meds

■ Still have to do the same basic evaluation, whether it's a prescribed drug or illicit drug:

Pattern of use/Risk/Problems/Control Use all available information from different sources Use appropriate drug screening

- Do need to get information from the *prescribing clinician* Indication for med/Patterns of use/Problems Information about the prescriber
- Evaluate for abuse or addiction but also for *co-morbidities*



<u>Individuals change when:</u>

- They believe they have a problem (DiClemente, 1991)
- They feel they can be effective (Bandura, 1977)
- They participate in setting the goals (Ockene, 1988)

Patient-Treatment Matching

Project MATCH

- Prospective, randomized design MI/CBT/12 Step Facilitation
- >1000 patients, over 4 years, with >90% follow-up
- 90% Reduction in drinking seen by week 2 of study (drinks per drinking day, drinking days in prior month)
- No significant differences in outcome found between 3 options.

Patient-Treatment Matching

ASAM Patient Placement Criteria

Useful in multi-dimensional care planning

- Withdrawal Risks
- Biomedical Conditions
- Emotional and Behavioral Conditions
- Readiness to Change (Treatment Resistance)
- Relapse/Continued Use Potential
- Recovery Environment

Patient-Treatment Matching

ASAM Patient Placement Criteria

- Preliminary studies show validity of model and predictive utility for treatment assignment
- Widely used tool
- Has helped build consensus among a broad range of health care agents and treatment providers

Monitor for Effectiveness/Outcome

- Monitor not just in terms of sobriety/abstinence
- Monitor in terms of functional improvement:
 - -emotional
 - -interpersonal
 - -medical
 - -occupational
 - -legal

Adapting Treatment Based on Ongoing Assessment and Outcome

- Increase level of care
- Improve recovery environment
 - Joblessness
- Homelessness
- Substance users in living environment
- Assess treatment for co-morbid psych problems
- Leverage what is different since last contact?
- What follow-up plans did he complete/not complete?
- What is going well, what not so well?
- Is there now a need for medication assisted treatment?

| _ | | | |
|---|--|--|--|
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| _ | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |

Further Adaptation as Indicated

- Rearrange reinforcements
- Reassess for ambivalence re change process
- Increase self-efficacy: build on successes
- Increase skills for tolerating negative affects
- Client-centered treatment strategies in association with confrontation

Change Mechanisms and Efficacy How Can We Do Better?

Take advantage of what we know:

- Utilize pharmacologic and non-pharmacologic treatment approaches that research shows are most effective
- Adapt treatments dependent on outcome/progress

Take advantage of all opportunities to:

- Use motivational approach to keep patients engaged with treatment
- Adapt treatments to address patients at various stages of change